Kairos Pharma’s (KAPA) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Kairos Pharma (NYSEAMERICAN:KAPA) in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $9.00 price target on the stock.

Kairos Pharma Stock Performance

KAPA opened at $1.33 on Tuesday. Kairos Pharma has a 52 week low of $0.85 and a 52 week high of $4.00.

About Kairos Pharma

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.